These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15830188)

  • 1. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.
    Ionut V; Hucking K; Liberty IF; Bergman RN
    Diabetologia; 2005 May; 48(5):967-75. PubMed ID: 15830188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
    Nishizawa M; Moore MC; Shiota M; Gustavson SM; Snead WL; Neal DW; Cherrington AD
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E1027-36. PubMed ID: 12569088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
    Burcelin R; Da Costa A; Drucker D; Thorens B
    Diabetes; 2001 Aug; 50(8):1720-8. PubMed ID: 11473030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.
    Dardevet D; Moore MC; Neal D; DiCostanzo CA; Snead W; Cherrington AD
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E75-81. PubMed ID: 15026303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
    Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1085-91. PubMed ID: 17684104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
    Toft-Nielson M; Madsbad S; Holst JJ
    Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.
    Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E380-4. PubMed ID: 18056788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways.
    Nishizawa M; Nakabayashi H; Uehara K; Nakagawa A; Uchida K; Koya D
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(3):E376-87. PubMed ID: 23715725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
    Vahl TP; Tauchi M; Durler TS; Elfers EE; Fernandes TM; Bitner RD; Ellis KS; Woods SC; Seeley RJ; Herman JP; D'Alessio DA
    Endocrinology; 2007 Oct; 148(10):4965-73. PubMed ID: 17584962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of oral, peripheral intravenous, and intraportal glucose on hepatic glucose uptake and insulin and glucagon extraction in conscious dogs.
    Ishida T; Chap Z; Chou J; Lewis R; Hartley C; Entman M; Field JB
    J Clin Invest; 1983 Aug; 72(2):590-601. PubMed ID: 6348094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs.
    Veedfald S; Hansen M; Christensen LW; Larsen SA; Hjøllund KR; Plamboeck A; Hartmann B; Deacon CF; Holst JJ
    Exp Physiol; 2016 Jul; 101(7):895-912. PubMed ID: 27027735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
    Nikolaidis LA; Elahi D; Hentosz T; Doverspike A; Huerbin R; Zourelias L; Stolarski C; Shen YT; Shannon RP
    Circulation; 2004 Aug; 110(8):955-61. PubMed ID: 15313949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.